Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMRT alone versus concurrent cisplatin chemoradiotherapy for moderate-risk nasopharyngeal carcinoma
ChiCTR1800017132Phase 2Recruiting
- Sponsor
- The First Affiliated Hospital of Guilin Medical University
- Start
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of cisplatin in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by The First Affiliated Hospital of Guilin Medical University. Primary endpoints: Progression-free survival and Toxicities. Started Jul 2018; status: recruiting.
02
Drugs
cisplatin
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR1800017132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800017132.